2-hydroxy-naphtho[1,2,3-de]quinolin-7-one | 6248-10-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 2-hydroxy-naphtho[1,2,3-de]quinolin-7-one
• 英文别名: 2-Hydroxy-naphtho[1,2,3-de]chinolin-7-on；2-Hydroxyanthrapyridine；2-Hydroxyanthrapyridin；14-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2,4,6,9(17),10,12-heptaene-8,15-dione
• CAS: 6248-10-8
• 化学式: C₁₆H₉NO₂
• 分子量: 247.253
• InChiKey: CTSKAPUYEZZYQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-hydroxy-naphtho[1,2,3-de]quinolin-7-one 在 三氯氧磷 作用下， 反应 3.0h， 以98%的产率得到2-chloro-7H-dibenz[f,ij]isoquinoline-7-one
  参考文献：
  名称：

  7-氧代-7H-二苯并[f，ij]异喹啉和7-氧代-7H-苯并[e]亚氨基吡啶衍生物的合成及细胞毒活性。

  摘要：

  从氨基蒽醌制备了一系列带有阳离子侧链的7-氧代-7H-二苯并[f，ij]异喹啉和7-氧代-7H-苯并[e]亚氨基。通过与尿素或二甲基乙酰胺的初始缩合，由1-氨基蒽醌制备过亚im啶。由氨基蒽醌羧酸制备了二苯并异喹啉的一系列2-，4-，8-和11-羧基衍生物。由这些经由酰胺，胺或亚甲基接头制备阳离子衍生物，以研究侧链定位对生物活性的影响。在一系列与羧酰胺连接的化合物中，增加的细胞毒性顺序为8-<4- <2- <11-。2-和4-羧酰胺对小鼠体内的皮下结肠38肿瘤表现出明显的生长延迟，

  DOI：

  10.1021/jm010041l
• 作为产物：
  描述：

  2-氯-N-(9,10-二氧代-9,10-二氢-1-蒽基)乙酰胺 在 水 、 碳酸氢钠 、 sodium hydrogensulfite 作用下， 生成 2-hydroxy-naphtho[1,2,3-de]quinolin-7-one
  参考文献：
  名称：

  Marschalk, Bulletin de la Societe Chimique de France, 1952, p. 949

  摘要：

  DOI：

文献信息

• Method for preparing light-absorbing polymeric compositions
  申请人：——

  公开号：US20040195552A1

  公开（公告）日：2004-10-07

  The present invention recites a method comprising reacting in a solvent in the presence of a base a) at least one diacidic monomer comprising about 1 to 100 mole % of at least one light-absorbing monomer having a light absorption maximum between about 300 nm and about 1200 nm and 99-0 mole % of a non-light absorbing monomer which does not absorb significant light at wavelengths above 300 nm or has a light absorption maximum below 300 nm, with b) an organic compound of Formula II X—B—X 1 wherein B is a divalent organic radical to form a light absorbing composition comprising a mixture of a polymer having the formula 1 and a cyclic compound having the general formula 2 wherein B is as defined above; n is at least 2, m is 1, 2, 3 or 4 and A comprises the residue of a diacidic monomer comprising about 1 to 100 mole % of at least one light-absorbing monomer having a light absorption maximum between about 300 nm and about 1000 nm and wherein the remaining portion of A comprises the residue of a non-light absorbing monomer which does not absorb significant light at wavelengths above 300 nm or has a light absorption maximum below 300 nm.

  本发明涉及一种方法，包括在溶剂中，在碱的存在下反应：a）至少一种二酸单体，其中包括约1至100摩尔％的至少一种具有在300nm至1200nm之间的光吸收最大值的光吸收单体和99-0摩尔％的不吸收在300nm以上波长处的显著光或具有在300nm以下的光吸收最大值的非光吸收单体；b）式IIX-B-X1的有机化合物，其中B是二价有机基团，以形成一种光吸收组合物，该组合物包括具有式1的聚合物和具有一般式2的环状化合物，其中B如上所定义；n至少为2，m为1、2、3或4，A包括约1至100摩尔％的至少一种具有在300nm至1000nm之间的光吸收最大值的光吸收单体的残基，其中A的其余部分包括不吸收在300nm以上波长处的显著光或具有在300nm以下的光吸收最大值的非光吸收单体的残基。
• Light pipe composition
  申请人：ROHM AND HAAS COMPANY

  公开号：EP0959372A2

  公开（公告）日：1999-11-24

  The present invention provides polymeric material compositions having excellent white light transmission that is substantially free of color over long light path lengths. This invention also provides polymeric material compositions that provide for the transmission of light having a controlled color when illuminated with a white light source.

  本发明提供的聚合材料组合物具有极佳的白光透射性，在较长的光路长度上基本无色差。本发明还提供了在白光光源照射下具有可控颜色透光性能的聚合物材料组合物。
• Colorant compounds containing copolymerizable vinyl groups
  申请人：EASTMAN CHEMICAL COMPANY

  公开号：EP1739135A2

  公开（公告）日：2007-01-03

  Disclosed are novel colorant compounds which contain one or more ethylenically-unsaturated (vinyl), photopolymerizable radicals which may be copolymerized (or cured) with ethylenically-unsaturated monomers to produce colored compositions such as colored acrylic coatings and polymers, e.g., coatings and polymers produced from acrylate and methacrylate esters, colored polystyrenes, and similar colored polymeric materials derived from other ethylenically-unsaturated monomers. The present invention also pertains to processes for the preparation of certain of the photopolymerizable colorant compounds.

  本发明公开了新型着色剂化合物，该化合物含有一种或多种乙烯基不饱和（乙烯基）、可光聚合的自由基，可与乙烯基不饱和单体共聚（或固化），以生产彩色组合物，如彩色丙烯酸涂料和聚合物，例如由丙烯酸酯和甲基丙烯酸酯生产的涂料和聚合物、彩色聚苯乙烯以及由其他乙烯基不饱和单体衍生的类似彩色聚合物材料。本发明还涉及某些可光聚合着色剂化合物的制备工艺。
• Screening methods for identifying specific Staphylococcus aureus inhibitors
  申请人：Guenther Richard H.

  公开号：US10316371B2

  公开（公告）日：2019-06-11

  Methods of inhibiting S. aureus propagation, and screening for compounds that inhibit S. aureus propagation, are described. A method of inhibiting S. aureus propagation comprises either inhibiting or stabilizing ribosomal binding of a specific S. aureus tRNA in the S. aureus by an amount sufficient to inhibit S. aureus protein expression. A method of screening for compounds useful for inhibiting S. aureus propagation comprises contacting a specific S. aureus tRNA to a ribosome that binds that tRNA in the presence of the test compound and an mRNA that codes for methionine and arginine (i.e., includes the sequence AUGAGA), and then determining whether the compound inhibits the binding of that tRNA.

  本文描述了抑制金黄色葡萄球菌繁殖的方法和筛选抑制金黄色葡萄球菌繁殖的化合物的方法。一种抑制金黄色葡萄球菌繁殖的方法包括抑制或稳定金黄色葡萄球菌中特定金黄色葡萄球菌 tRNA 的核糖体结合，其抑制量足以抑制金黄色葡萄球菌蛋白质的表达。筛选可抑制金黄色葡萄球菌繁殖的化合物的方法包括将特异的金黄色葡萄球菌tRNA与核糖体接触，该核糖体在试验化合物和编码蛋氨酸和精氨酸（即包括序列AUGAGA）的mRNA存在的情况下结合该tRNA，然后确定该化合物是否抑制该tRNA的结合。
• Compositions and methods for treating pulmonary hypertension
  申请人：Acceleron Pharma Inc.

  公开号：US10695405B2

  公开（公告）日：2020-06-30

  In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

  在某些方面，本公开涉及GDF/BMP拮抗剂和使用GDF/BMP拮抗剂治疗、预防或降低肺动脉高压（PH）进展率和/或严重程度的方法，特别是治疗、预防或降低一种或多种PH相关并发症的进展率和/或严重程度的方法。本公开还提供了使用GDF/BMP拮抗剂治疗、预防或降低各种病症（包括但不限于肺血管重塑、肺纤维化和右心室肥大）的进展速度和/或严重程度的方法。本公开进一步提供了使用 GDF/BMP 拮抗剂降低有需要的受试者右心室收缩压的方法。